Dorsey Asset Management LLC Reduces Stock Holdings in Danaher Corporation $DHR

Dorsey Asset Management LLC reduced its stake in shares of Danaher Corporation (NYSE:DHR) by 29.9% in the 1st quarter, Holdings Channel.com reports. The firm owned 580,240 shares of the conglomerate’s stock after selling 247,280 shares during the quarter. Danaher makes up 8.8% of Dorsey Asset Management LLC’s holdings, making the stock its 5th largest holding. Dorsey Asset Management LLC’s holdings in Danaher were worth $110,014,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the stock. Enterprise Financial Services Corp increased its holdings in shares of Danaher by 1.4% during the 4th quarter. Enterprise Financial Services Corp now owns 3,219 shares of the conglomerate’s stock worth $737,000 after purchasing an additional 46 shares during the period. Kennebec Savings Bank lifted its stake in shares of Danaher by 1.4% in the fourth quarter. Kennebec Savings Bank now owns 3,348 shares of the conglomerate’s stock valued at $766,000 after buying an additional 46 shares during the period. Revolve Wealth Partners LLC lifted its stake in shares of Danaher by 2.6% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,870 shares of the conglomerate’s stock valued at $428,000 after buying an additional 47 shares during the period. High Note Wealth LLC grew its position in Danaher by 19.2% during the fourth quarter. High Note Wealth LLC now owns 292 shares of the conglomerate’s stock worth $67,000 after buying an additional 47 shares in the last quarter. Finally, First Command Advisory Services Inc. increased its stake in Danaher by 4.4% during the fourth quarter. First Command Advisory Services Inc. now owns 1,104 shares of the conglomerate’s stock valued at $253,000 after acquiring an additional 47 shares during the period. 79.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on DHR shares. Rothschild & Co Redburn set a $205.00 price target on Danaher in a report on Friday, April 17th. Robert W. Baird decreased their price objective on Danaher from $251.00 to $249.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. The Goldman Sachs Group lowered their price objective on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a research report on Monday, April 13th. Weiss Ratings raised Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, July 15th. Finally, Argus decreased their price target on shares of Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a research note on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $228.91.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: J.P. Morgan reiterated a Buy rating on Danaher, which may help support investor confidence after the post-earnings pullback. J.P. Morgan Keeps Their Buy Rating on Danaher (DHR)
• Positive Sentiment: Several articles argue Danaher’s recent slump looks like an overreaction and could be a buying opportunity, suggesting the stock may recover if investors refocus on its long-term fundamentals. Here’s Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
• Positive Sentiment: Danaher’s quarterly results beat estimates, with EPS of $1.94 versus $1.85 expected and revenue of $6.27 billion above forecasts, which supports the case that core business performance remains solid. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
• Neutral Sentiment: Billionaire investor Dan Loeb reduced his Danaher stake in Q1 2026, adding to sentiment pressure around life sciences tools stocks, though it does not change Danaher’s operating results. Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets
• Neutral Sentiment: Danaher saw unusually heavy put option activity, signaling traders are hedging against more downside in the near term. Don’t Quit on Danaher Stock After Horrific Earnings Reaction

Danaher Stock Down 0.3%

Shares of DHR opened at $191.87 on Friday. The company has a quick ratio of 1.52, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The company has a 50-day moving average price of $185.64 and a two-hundred day moving average price of $197.04. The stock has a market cap of $134.88 billion, a price-to-earnings ratio of 34.08, a P/E/G ratio of 2.38 and a beta of 0.79. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period in the prior year, the company posted $0.77 EPS. The company’s revenue was up 5.5% compared to the same quarter last year. Equities analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Friday, June 26th. Danaher’s dividend payout ratio is 28.42%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.